Osteoporosis Testing Market to Witness Substantial Growth, Hitting USD 566.8 Million by 2030, Report by DataM Intelligence

Overview of the Osteoporosis Testing Market

The Osteoporosis Testing Market is rapidly gaining momentum as a crucial aspect of preventive healthcare, driven by the global rise in osteoporosis cases and improved awareness of early diagnosis methods. Osteoporosis, characterized by weakened bones and increased risk of fracture, often progresses silently until a break occurs, making timely detection critical. Advances in bone mineral density (BMD) measurement technologies, particularly dual-energy X-ray absorptiometry (DEXA) scans, quantitative computed tomography (QCT), and emerging AI-driven imaging platforms, are transforming clinical strategies for assessing bone health. With healthcare systems stressing cost-effective prevention and treatment of chronic diseases, accurate and accessible osteoporosis diagnostics are now at the heart of fracture risk reduction strategies, especially among aging populations and high-risk groups such as postmenopausal women.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/osteoporosis-testing-market?jd

According to DataM Intelligence, the global osteoporosis testing market size was valued at approximately USD 383.5 million in 2022 and is projected to reach about USD 566.8 Million by 2030, growing at a CAGR of 5.1% during the forecast period (2024-2031). Key growth drivers include the rising geriatric population, increasing prevalence of osteoporosis (especially among women), and government initiatives for early screening and prevention. DEXA scans are the gold-standard diagnostic method, holding the largest market share due to their accuracy and non-invasive nature. North America dominates as the leading region, backed by advanced healthcare infrastructure, high healthcare spending, and proactive public health campaigns to address bone disease, while Asia-Pacific is emerging as a high-growth region due to the rapid increase in its aging population and expanding healthcare access.

Key Highlights from the Report

➤ DEXA scans remain the gold standard, dominating the product segment for osteoporosis diagnosis.
➤ North America leads with over 38% share due to high disease prevalence and robust healthcare infrastructure.
➤ Asia-Pacific is the fastest-growing region, fueled by rising elderly population and improved healthcare access.
➤ AI and point-of-care testing technologies are emerging as transformative trends in osteoporosis diagnostics.
➤ Key end users are hospitals, diagnostic imaging centers, and orthopedic clinics, embracing innovation to enhance patient outcomes.

Market Segmentation

By Type: The osteoporosis testing market includes DEXA scans, FRAX tools, CT scans, X-rays, and other diagnostic methods. DEXA remains the gold standard for bone density measurement, while FRAX and imaging techniques complement risk assessment and fracture prediction.

By End User: End users comprise hospitals, diagnostic centers, orthopedic clinics, and others. Hospitals and diagnostic centers dominate due to advanced imaging facilities, while orthopedic clinics focus on targeted screening and patient-specific bone health management.

Regional Insights

North America dominates the global osteoporosis testing market, capturing over 38% of the share. The region's leadership is owed to a high prevalence of osteoporosis and related fractures, a large elderly population, comprehensive insurance coverage, and substantial investment in healthcare technology and public health campaigns. In the U.S., osteoporosis affects nearly 10 million people, with millions more at risk due to low bone density. Regulatory support, reimbursement models, and robust R&D environments foster the introduction of advanced diagnostics and targeted screening programs.

Europe holds significant share, driven by aging demographics, preventive health priorities, and cohesive healthcare strategies that encourage early osteoporosis detection and management.

Asia-Pacific is the fastest-growing regional market, underpinned by explosive demographic aging in countries such as China and Japan, increasing awareness, and government healthcare investments focused on chronic disease prevention. Enhanced access to healthcare and technology adoption is supporting rapid market expansion.

Latin America, Middle East, and Africa are smaller but steadily developing markets where increasing awareness, rising healthcare expenditures, and the introduction of cost-effective, portable diagnostics are driving uptake.

Market Drivers

The osteoporosis testing market's growth is powered by an aging global population, rising disease prevalence, and a clear clinical need for early and accurate diagnosis to prevent debilitating fractures. Government programs and awareness initiatives increasingly target women and other high-risk groups, while technological advances in imaging and AI-based analysis strengthen accuracy, efficiency, and access. Preventive healthcare's evolution toward minimizing chronic disease burden further boosts market demand, and the development of minimally invasive or portable diagnostic solutions is making bone health assessment more widely available.

Market Restraints

Challenges include high costs for advanced testing equipment (e.g., DEXA and QCT scanners), especially in resource-limited settings, and limited reimbursement schemes for screening in some countries. Access disparities and limited awareness about the benefits of early screening remain significant barriers in developing and rural areas. Reimbursement, regulatory hurdles, and a traditional focus on symptomatic patients (rather than preventive screening) limit full market penetration for newer technologies and approaches.

Market Opportunities

Major opportunities lie in integrating AI-powered image analysis to enhance diagnostic precision, developing portable and low-cost testing devices to expand access in primary care and emerging markets, and combining biochemical markers with imaging for multi-modal fracture risk assessment. The growing emphasis on personalized and preventive medicine is expected to further drive demand for advanced diagnostics. Partnerships among device manufacturers, software companies, and healthcare providers are expected to accelerate innovation and adoption.

Do You Have Any Queries or Specific Requirements? Request Customization of Report: https://www.datamintelligence.com/customize/osteoporosis-testing-market?jd

Reasons to Buy the Report

✔ Access the latest, clinically relevant, and commercially actionable osteoporosis testing market insights.
✔ Analyze leading diagnostic technologies - DXA, QCT, AI, and point-of-care innovations, and future trends.
✔ Benchmark strategies, partnerships, and product innovation for both multinational corporations and emerging players.
✔ Understand country-level reimbursement, regulation, and market access factors.
✔ Identify emerging investment and growth opportunities across established and high-growth geographies.

Frequently Asked Questions (FAQs)

How big is the osteoporosis testing market and how fast is it growing?
Who are the leading players in the global osteoporosis testing market?
What is the market forecast for advanced techniques like AI-powered and point-of-care osteoporosis testing?
Which end users hospitals, clinics, imaging centers drive market demand for diagnostics?
Which regions are anticipated to lead the osteoporosis testing market during the forecast period?

Company Insights

• GE Healthcare
• Hologic Inc.
• DMS Imaging
• Swissray
• Merck
• B.M.Tech. Worldwide
• Pfizer
• BeamMed Ltd
• CompuMed
• Eli Lilly
• Scanflex Healthcare

Recent Developments:

In July 2025, Osteoboost Health unveiled its FDA-cleared prescription wearable device, a breakthrough, drug-free solution targeting low bone density through vibration therapy aimed at the spine and hips. Beyond launch, Osteoboost secured strategic funding from leading investors and completed the acquisition of Wellen, a fall-prevention and exercise platform for women with low bone density.

In June 2025, the US Preventive Services Task Force (USPSTF) issued updated guidelines reinforcing the importance of DEXA (dual-energy X-ray absorptiometry) screening for osteoporosis particularly for women aged 65+, and younger postmenopausal women with risk factors. This renewed emphasis cements DEXA's role as the gold standard in early detection.

Conclusion

As the world's population ages and the clinical and economic impact of osteoporosis rises, testing for bone fragility and fracture risk is becoming central to preventive healthcare. The osteoporosis testing market is capitalizing on advances in imaging, AI, and portable diagnostics to enable earlier, more accurate, and more accessible detection. North America leads with mature infrastructure and policy, while Asia-Pacific's rapidly aging societies promise accelerated growth. Despite challenges surrounding cost, access, and awareness, the sector's future is bright, with continued innovation, public health initiatives, and cross-sector partnerships expanding the reach and power of osteoporosis diagnostics worldwide.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence:

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.